AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Creon (pancrelipase) — U.S. reported growth YoY by Year
Creon (pancrelipase) — U.S. reported growth YoY (%) (%)
AbbVie Creon (pancrelipase) — U.S. reported growth YoY: 9.3% in FY2025, up 0.2 pts from a year earlier.
Latest, FY2025
9.3%
Period ended Dec 31, 2025
Change on a year earlier
+0.2 pts
9.1% in FY2024
History
9 years
Since FY2017
Sources
9
Documents cited below
Where the FY2025 figure comes from
“|| Creon | 1,512 | — | 1,512 | 9.3 | n/m | 9.3 | n/m | 9.3”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Creon (pancrelipase) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.3% | +0.2 pts | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 9.1% | +9.9 pts | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | -0.8% | -8.1 pts | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 7.3% | +0.4 pts | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 6.9% | 0.0 pts | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 6.9% | -5.3 pts | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 12.2% | +0.5 pts | Form 8-K (abbv-20191231xexhibit9.htm, filed 2020-02-07) ↗ |
| FY2018 | Dec 31, 2018 | 11.7% | -2.2 pts | Form 8-K (abbv-20181231xexhibit991.htm, filed 2019-01-25) ↗ |
| FY2017 | Dec 31, 2017 | 13.9% | – | Form 8-K (abbv-20171231xexhibit991.htm, filed 2018-01-26) ↗ |
Cite this data
StockData. (2026). AbbVie Creon (pancrelipase) — U.S. reported growth YoY (%), annual FY2017–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/creon-us-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.